Department of General Surgery, Civil Aviation General Hospital, No.1 Gaojing, Chaoyang Street, Beijing, China.
Key Laboratory of Endocrinology of National Health Commission, Department of Endocrinology, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.
Asian Pac J Cancer Prev. 2021 Apr 1;22(4):991-997. doi: 10.31557/APJCP.2021.22.4.991.
Epidemiological studies have showed that vitamin D deficiency can increase the risk of liver cancers. Hence, we conducted a meta-analysis to explore the relationship between 25-hydroxyvitamin D [25(OH)D] levels and liver cancer risk.
Cochrane Library, Medline, Web of Science, and Embase were searched up to Mar. 2020, and the references of those studies were also searched by hand. A meta-analysis of 11 studies was performed which met the inclusion criteria. Six case-control studies and five cohort studies were included.
A total of 11 studies (6 case-control and 5 cohort studies) with 12,895 incident cases were included in the meta-analysis. The meta-analysis showed that liver cancer risk was significantly increased for vitamin D deficiency, and the pooled RR and its 95% CIs was 2.16 (1.2, 3.88; P = 0.01). In comparative analyses between 25(OH)D levels in patients with hepatocellular carcinoma(HCC) and those in the control group individuals, the summary RR of liver cancer was -1.11 (95% CI=-1.96 to -0.25). The subgroup analysis of the different geographical region of the population showed that the risk of liver cancer in Asian subgroup, European subgroup and Egyptian subgroup increased for vitamin D deficiency (RR=1.34,95% CI 0.72 to 2.48, p <0.00001; RR=2.53,95% CI 1.62 to 3.93,p <0.0001;RR=29.5,95% CI 4.14 to 209.93, P=0.88).
The results of this meta-analysis indicate that vitamin D deficiency is associated with increased risk of liver cancer. The 25(OH)D3 levels are lower in HCC patients than those in health controls. Maintenance of sufficient serum vitamin D levels would be beneficial for prevention of liver cancer.
流行病学研究表明，维生素 D 缺乏会增加肝癌的风险。因此，我们进行了一项荟萃分析，以探讨 25-羟维生素 D [25(OH)D]水平与肝癌风险之间的关系。
检索 Cochrane 图书馆、Medline、Web of Science 和 Embase，截至 2020 年 3 月，并通过手工检索这些研究的参考文献。对符合纳入标准的 11 项研究进行了荟萃分析。纳入了 6 项病例对照研究和 5 项队列研究。
共纳入 11 项研究（6 项病例对照研究和 5 项队列研究），共计 12895 例肝癌新发病例。荟萃分析显示，维生素 D 缺乏与肝癌风险显著增加相关，合并 RR 及其 95%可信区间为 2.16（1.2，3.88；P = 0.01）。在比较肝癌患者和对照组个体 25(OH)D 水平的分析中，肝癌的汇总 RR 为-1.11（95% CI=-1.96 至-0.25）。根据人群的不同地理区域进行的亚组分析显示，亚洲亚组、欧洲亚组和埃及亚组维生素 D 缺乏与肝癌风险增加相关（RR=1.34，95% CI 0.72 至 2.48，P<0.00001；RR=2.53，95% CI 1.62 至 3.93，P<0.0001；RR=29.5，95% CI 4.14 至 209.93，P=0.88）。
本荟萃分析结果表明，维生素 D 缺乏与肝癌风险增加有关。肝癌患者的 25(OH)D3 水平低于健康对照者。维持足够的血清维生素 D 水平将有利于预防肝癌。
